TSX:MBX - Post Discussion
Post by
Betteryear2 on Feb 14, 2024 2:40pm
Microbix Reports Record Results for Q1 Fiscal 2024
MISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2024 ended December 31, 2023 (“Q1”), with record quarterly revenues and a record quarterly profit, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices, and material licensing revenues from its fully-funded program to revalidate and relaunch its approved drug, Kinlytic® urokinase (“Kinlytic”). Microbix Reports Record Results for Q1 Fiscal 2024 (globenewswire.com)
Be the first to comment on this post